Business
Ensysce Biosciences Reports First Quarter 2026 Financial Results
~ IRB Approval Secured for PF614-MPAR-102 Part 3 ~ ~ Clinical Peer-Reviewed Data Published for First Overdose Protected Opioid PF614-MPAR®; Patent Estate Expanded ~ ~ Company Launches Formal Review of Strategic Alternatives ~ SAN DIEGO, CA / ACCESS ...
About this update from Ensysce Biosciences, Inc.
[{"type":"text","content":"~ IRB Approval Secured for PF614-MPAR-102 Part 3 ~","length":50,"tagName":"p"},{"type":"text","content":"~ Clinical Peer-Reviewed Data Published for First Overdose Protected Opioid PF614-MPAR®; Patent Estate Expanded ~","length":121,"tagName":"p"},{"type":"text","content":"~ Company Launches Formal Review of Strategic Alternatives ~","length":60,"tagName":"p"},{"type":"text","content":"SAN DIEGO, CA / ACCESS Newswire / May 15, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics engineered to minimize abuse and overdose risk, today reported financial and operational results for the first quarter ended March 31, 2026.","length":391,"tagName":"p"},{"type":"text","content":""The first quarter of 2026 delivered meaningful operational and clinical momentum across our pipeline, underscoring the strength of our strategy and the discipline of our execution," said Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce. We achieved 50% of the interim enrollment target in our pivotal PF614-301 Phase 3 trial, published the first peer-reviewed clinical data validating our MPAR® overdose-protection technology, and expanded our patent estate across both our opioid and ADHD programs. Together these milestones reinforce what we believe is the next evolution of opioid safety."","length":616,"tagName":"p"},{"type":"text","content":"Dr. Kirkpatrick continued, "Following quarter-end, we closed a second financing tranche under an existing facility and secured IRB approval to initiate Part 3 of PF614-MPAR-102, the final stage of that study. Advancing this program strengthens the clinical evidence supporting a product we believe can fundamentally reshape how overdose risk is managed. In parallel, our Board has initiated a formal review of strategic alternatives, including potential partnerships and licensing opportunities, to accelerate the development of our TAAP™ and MPAR® platforms and unlock additional shareholder value."","length":610,"tagName":"p"},{"type":"text","content":"TAAP™ (Opioid Abuse Deterrent Program) Update","length":45,"tagName":"p"},{"type":"text","content":"PF614 is the Company's lead product candidate and represents what we believe could b...